<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679729</url>
  </required_header>
  <id_info>
    <org_study_id>D6600C00001</org_study_id>
    <nct_id>NCT02679729</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better
      understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I, FIH, randomized, single-blinded (study center staff remain blinded
      during the dosing phase of the study), placebo-controlled, single ascending dose, sequential
      dose group study in healthy male subjects and/or female subjects of non-childbearing
      potential at a single study center to assess AZD5634 following inhaled and intravenous dose
      administration
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2016</start_date>
  <completion_date type="Actual">October 24, 2016</completion_date>
  <primary_completion_date type="Actual">October 24, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequencies of adverse events</measure>
    <time_frame>From screening to 2 months post final dose</time_frame>
    <description>To assess the frequencies of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of adverse events</measure>
    <time_frame>From screening to 2 months post final dose</time_frame>
    <description>To assess the percentages of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supine heart rate</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess change from baseline in supine heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supine blood pressure</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess change from baseline in supine blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supine pulse oximetry</measure>
    <time_frame>From screening to up to 10 days postdose</time_frame>
    <description>To assess change from baseline in supine pulse oximetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supine respiratory rate</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess change from baseline in supine respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supine body temperature</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess change from baseline in supine body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>during study days 1 and 2</time_frame>
    <description>To assess 12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram (cardiac telemetry)</measure>
    <time_frame>Part A: From day -1 to 24 hours postdose; Part B: From day -1 to 48 hours postdose</time_frame>
    <description>To assess the cardiac telemetry by telemetry monitoring system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety electrocardiogram</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess safety electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemistry evaluations</measure>
    <time_frame>From screening to 2 months postdose</time_frame>
    <description>To assess chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology evaluations</measure>
    <time_frame>From screening to 2 months postdose</time_frame>
    <description>To assess hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>From screening up to 10 days postdose</time_frame>
    <description>To assess subject through a physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry</measure>
    <time_frame>From screening to 2 months postdose</time_frame>
    <description>To assess spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine collection</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To assess fractional excretion of potassium and transtubular potassium gradient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis evaluations</measure>
    <time_frame>From screening to 2 months postdose</time_frame>
    <description>To assess urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration, taken directly from the individual concentration-time curve (Cmax)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under concentration-time curve from time zero extrapolated to infinity (AUC)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)]</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute systemic bioavailability after inhalation (Part B only) (Finhalation,total)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of AZD5634 excreted into the urine from time t1 to t2 [Ae(t1-t2)]</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of AZD5634 excreted into the urine at the last sampling interval [Ae(0-last)]</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose excreted unchanged into the urine from time zero to the last measured time point for AZD5634 estimated by dividing Ae(0-last) by dose [fe(0-last)]</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dose excreted unchanged into the urine from time zero to the last measured time point for AZD5634 estimated by dividing Ae(0-last) by dose [fe(0-last)%]</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr), estimated by dividing Ae(0-last) by AUC0-t</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, divided by the dose administered (Cmax/Dose)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration, taken directly from the individual concentration-time curve (tmax)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2λz), estimated as (ln2)/λz</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t, divided by the dose administered (AUC0-t/Dose)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC, divided by the dose administered (AUC/Dose)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance for AZD5634 estimated as dose divided by AUC (Part B IV dosing only) (CL)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance for AZD5634 estimated as dose divided by AUC (Part A and Part B inhaled dosing only) (CL/F)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absorption Time, calculated as MRTinhaled - MRTIV (Part B only) (MAT)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution for AZD5634 at steady state (IV administration), estimated by dividing the MRT by the systemic CL (Part B IV dosing only) (Vss)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution for AZD5634 at terminal phase (IV administration), estimated by dividing the systemic CL by λz (Part B IV dosing only) (Vz)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution for AZD5634 at terminal phase (inhaled administration), estimated by dividing the CL/F by λz (Part A and Part B inhaled dosing only) (Vz/F)</measure>
    <time_frame>From predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)]</measure>
    <time_frame>From 12 hours predose to 48 hours postdose</time_frame>
    <description>To characterize the pharmacokinetics of AZD5634</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A, Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5634 for inhalation</intervention_name>
    <description>Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer</description>
    <arm_group_label>Part A, Dose Level 1</arm_group_label>
    <arm_group_label>Part A, Dose Level 2</arm_group_label>
    <arm_group_label>Part A, Dose Level 3</arm_group_label>
    <arm_group_label>Part A, Dose Level 4</arm_group_label>
    <arm_group_label>Part A, Dose Level 5</arm_group_label>
    <arm_group_label>Part A, Dose Level 6</arm_group_label>
    <arm_group_label>Part A, Dose Level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5634 for infusion</intervention_name>
    <description>Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL</description>
    <arm_group_label>Part B, Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inactive substance</description>
    <arm_group_label>Part A, Dose Level 1</arm_group_label>
    <arm_group_label>Part A, Dose Level 2</arm_group_label>
    <arm_group_label>Part A, Dose Level 3</arm_group_label>
    <arm_group_label>Part A, Dose Level 4</arm_group_label>
    <arm_group_label>Part A, Dose Level 5</arm_group_label>
    <arm_group_label>Part A, Dose Level 6</arm_group_label>
    <arm_group_label>Part A, Dose Level 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          2. Healthy male and/or female subjects aged 18 - 50 years with suitable veins for
             cannulation or repeated venipuncture.

          3. Females must have a negative pregnancy test at screening and on admission to the unit,
             must not be lactating and must be of non-childbearing potential, confirmed at
             screening by fulfilling 1 of the following criteria:

               -  Post-menopausal defined as amenorrhea for at least 12 months or more following
                  cessation of all exogenous hormonal treatments and follicle-stimulating hormone
                  (FSH) levels in the post-menopausal range.

               -  Documentation of irreversible surgical sterilization by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy, but not tubal ligation.

          4. Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weigh at least 50
             kg and no more than 100 kg, inclusive.

          5. Have a FEV1 (Forced expiratory volume in 1 second in liters) ≥ 80% of the predicted
             value at screening.

          6. Provision of signed, written and dated informed consent for optional genetic/biomarker
             research.

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study.

          2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs.

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the administration of investigational medicinal product (IMP).

          4. Any clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis results, as judged by the investigator.

          5. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV).

          6. Abnormal vital signs, after 10 minutes supine rest, at screening and check-in, defined
             as any of the following:

               -  Systolic blood pressure (SBP) &lt; 90mmHg (millimeter of mercury) or ≥ 140 mmHg

               -  Diastolic blood pressure (DBP) &lt; 50mmHg or ≥ 90 mmHg

               -  Heart Rate &lt; 45 or &gt; 85 beats per minute (bpm)

          7. Any clinically significant abnormalities in rhythm, conduction or morphology of the
             resting electrocardiogram (ECG) and any clinically significant abnormalities in the
             12-lead ECG, as considered by the investigator that may interfere with the
             interpretation of QTc (QT [ECG interval measured from the onset of the QRS complex to
             the end of the T wave] interval corrected for heart rate) interval changes, including
             abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or
             left ventricular hypertrophy, at screening.

          8. PR (PQ [ECG interval measured from the onset of the P wave to the onset of the QRS
             complex]) interval prolongation (&gt; 240 ms) intermittent second (Wenckebach block while
             asleep is not exclusive) or third degree atrioventricular (AV) block, or AV
             dissociation, at screening.

          9. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle
             branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS &gt; 110 ms.
             Subjects with QRS (ECG interval measured from the onset of the QRS complex to the J
             point) &gt; 110 ms but &lt; 115 ms are acceptable if there is no evidence of, for example,
             ventricular hypertrophy or pre-excitation, at screening.

         10. Serum/plasma potassium levels are outside the normal range and lower than 3.5 to 5.1
             mEq/L (milliequivalents per liter) at screening and prior to dosing.

         11. Has active lung disease/asthma that requires treatment.

         12. Known or suspected history of drug abuse, as judged by the investigator.

         13. Current smokers or those who have smoked or used nicotine products within the previous
             3 months.

         14. History of alcohol abuse or excessive intake of alcohol, as judged by the
             investigator.

         15. Positive screen for drugs of abuse, cotinine (nicotine), or alcohol at screening or
             admission to the unit.

         16. History of severe allergy/hypersensitivity or ongoing clinically significant
             allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity
             to drugs with a similar chemical structure or class to AZD5634.

         17. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate),
             as judged by the investigator.

         18. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks
             prior to the administration of IMP.

         19. Use of any prescribed or non-prescribed medication including antacids, analgesics
             (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of
             20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to
             the administration of IMP or longer if the medication has a long half-life.

         20. Plasma donation within 1 month of screening or any blood donation/blood loss &gt; 500 mL
             during the 3 months prior to screening.

         21. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 3 months of the administration of IMP in this study.
             The period of exclusion is 3 months after the final dose from a previous study.

             Note: Subjects consented and screened, but not randomized in this study or a previous
             phase I study, are not excluded.

         22. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,
             trusteeship, or committed to an institution by governmental or juridical order.

         23. Involvement of any Astra Zeneca, PAREXEL or study site employee or their close
             relatives.

         24. Judgment by the investigator that the subject should not participate in the study if
             they have any ongoing or recent (i.e., during the screening period) minor medical
             complaints that may interfere with the interpretation of study data or are considered
             unlikely to comply with study procedures, restrictions and requirements.

         25. Subjects who are vegans or have medical dietary restrictions.

         26. Subjects who cannot communicate reliably with the investigator.

             In addition, any of the following is regarded as a criterion for exclusion from the
             genetic research:

         27. Previous bone marrow transplant.

         28. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
             genetic sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MDCM, M.Sc, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inhaled dose</keyword>
  <keyword>intravenous dose</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>AZD5634</keyword>
  <keyword>jet nebulizer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 11, 2017</submitted>
    <returned>February 23, 2018</returned>
    <submitted>March 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

